{"id":"NCT00824265","sponsor":"Novartis Pharmaceuticals","briefTitle":"Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia","officialTitle":"A Phase III, Open Label, Randomized Trial of Ofatumumab Added to Fludarabine-Cyclophosphamide vs. Fludarabine-Cyclophosphamide Combination in Subjects With Relapsed Chronic Lymphocytic Leukemia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-03-12","primaryCompletion":"2014-12-17","completion":"2017-10-25","firstPosted":"2009-01-16","resultsPosted":"2016-07-25","lastUpdate":"2020-06-18"},"enrollment":365,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Leukaemia, Lymphocytic, Chronic"],"interventions":[{"type":"DRUG","name":"OFC Infusion","otherNames":[]},{"type":"DRUG","name":"FC infusion","otherNames":[]}],"arms":[{"label":"Ofatumumab, Fludarabine, Cyclophosphamide","type":"EXPERIMENTAL"},{"label":"Fludarabine, Cyclophosphamide","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study was to evaluate the safety and efficacy of ofatumumab added to fludarabine-cyclophosphamide in patients with relapsed Chronic Lymphocytic Leukemia (CLL).","primaryOutcome":{"measure":"Progression-free Survival (PFS), as Assessed by the Independent Review Committee (IRC)","timeFrame":"From randomization up to 5 years after last dose of study drug","effectByArm":[{"arm":"Ofatumumab + Fludarabine + Cyclophosphamide_ ITT Subjects","deltaMin":28.94,"sd":null},{"arm":"Fludarabine + Cyclophosphamide_ ITT Subjects","deltaMin":18.83,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0032"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":10},"locations":{"siteCount":135,"countries":["United States","Brazil","Bulgaria","Canada","Germany","Greece","India","Italy","Mexico","Netherlands","Poland","Romania","Russia","Spain","Taiwan","Thailand","Ukraine","United Kingdom"]},"refs":{"pmids":["27830957","27731748","25103870"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":108,"n":181},"commonTop":["Neutropenia","Thrombocytopenia","Nausea","Anaemia","Vomiting"]}}